Best of ASCO - 2014 Annual Meeting

 

Welcome

New Targets and New Technologies (non-IO)

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A comparative analysis of RNA sequencing methods with ribosome RNA depletion for degraded and low-input total RNA from formalin-fixed and paraffin-embedded samples.

Xiaojing Lin

e14654

A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.

Elizabeth Ruth Plummer

3094

A general approach to optimizing tumor treating fields therapy.

Zeev Bomzon

e14668

A novel function for cyclin D1 as a transcriptional role in oncogenesis and tumor development by ChIP-Seq and RNA-Seq.

Yudi Xiong

e14628

A novel mutant-allele capture method for enrichment of low abundant cancer mutants.

Rui Lin

e14632

A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.

Priya Kumthekar

3012

A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors.

Erkut Hasan Borazanci

TPS3163

A phase I open label study evaluating VT1021 in patients with advanced solid tumors.

Michael Cieslewicz

TPS3158

A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.

Patrick Schoffski

TPS3162

A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).

Mihaela C. Cristea

3009

A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.

Safi Shahda

3097

A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.

Melissa Lynne Johnson

3098

A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.

Udai Banerji

3095

A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

Kyriakos P. Papadopoulos

TPS3161

A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.

David S. Hong

3091

A randomized phase 0 trial of the mitochondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC).

Miguel Quintela-Fandino

3100

A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies.

Mohammad Telfah

TPS3165

ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo.

Puey Ling Chia

e14677

AcornFusion: A novel tool to detect gene fusion events in DNA-Seq data.

Lifang Yao

e14650

Bioinformatic inspired nanoparticles engineered for enhanced delivery to the bone.

Andrew Gdowski

e14637

c-AMP/MAPK dysregulation and its impact on survival and response to immunotherapy in advanced melanomas.

Rami Al-Rohil

3086

Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer.

Atsushi Takano

e14627

Combination mTORC1/2 and BCL- XL inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.

Sarah Sammons

e14653

DDP4 inhibitors as novel agents in improving survival in diabetic patients with CRC and lung cancer: A SEER-Medicare study.

Rohit Bishnoi

e14633

Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving anticancer treatment.

Kuo-Ming Yu

3090

Differentiated pharmacokinetic and pharmacodynamic properties of a highly selective MET kinase inhibitor, OMO-1: Implications for efficacy and safety.

Timothy Pietro Suren Perera

e14674

Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience.

Angelika Terbuch

3088

Effect of PGK1 on radiosensitivity through regulation of CIN and CFL1 in human glioma cells.

Hongyi Liu

e14631

Effect of therapeutic GAS6/AXL inhibition of tumor and stromal cells on DNA damage and response to chemotherapy in ovarian cancer.

Mary M Mullen

e14676

Effect on tumor growth by TGF-β1/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice.

Michael Molyneaux

e14652

Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.

Olivia Le Saux

TPS3159

FGFR2: A pan-genomic target.

Russell Madison

3099

First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using 89Zr-Df-CPC634 PET/CT.

Iris H.C. Miedema

3093

First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.

Jeeyun Lee

3104

First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

Judy Sing-Zan Wang

3085

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

Johann S. De Bono

3007

FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.

David Michael Hyman

TPS3157

Identification of new targets and biomarkers in lung cancer.

Ioannis Papasotiriou

e14656

Impact on U251 glioma cell radiosensitivity and CFL1 level via inhibiting cell motility regulator ROCKII of RhoA-RockII-CFL1 pathway.

Mengjie Zhao

e14630

Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma.

Maria Vilenchik

e14670

Innovative dual system for selective eradication of cancer cells using exosomes carrying natural bacterial toxin-antitoxin (TA).

Shiran Shapira

e14635

Integrating CRISPR screening with tumor genomic analyses to identify therapeutic targets in hepatocellular carcinomas (HCC) independent of P53.

Ankur Sheel

e14659

Mechanistic study of the superior anti-cancer properties of a first-in-class small molecule targeting PCNA.

Long Gu

e14636

Meta-analysis of toxicity data in thoracic and abdominal malignancies from: Clinical trials in tumor treating fields.

Ignace Vergote

e14658

Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.

Marcelo Vailati Negrao

3102

Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC).

Katia Khoury

e14651

Nanoparticle entrapped docetaxel (CPC634) enhances intratumoral docetaxel exposure compared to conventional docetaxel (Cd) in patients with solid tumors.

Florence Atrafi

3096

NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.

Anita Ahmed Turk

e14640

Non-inferiority of a new advanced dry plasma thawing system compared to leading standard method: Preservation of coagulation and anticoagulation proteins necessary for use in the clinic.

Farideh Z. Bischoff

e14675

Oncology precision medicine for hepatobiliary and pancreatic cancer: An institutional review.

Geoffrey Bellini

e14626

Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.

Hao Xie

3101

Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma.

Lorena Farinas-Madrid

3089

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Marwan Fakih

3003

Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.

Mark J. Ratain

3013

Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

Victor Moreno

3015

Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.

Martin Kelly Nicholas

TPS3164

PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.

Juanita Suzanne Lopez

3087

Pooled analysis of onapristone extended release (ONA ER) in metastatic cancer patients (pts): A review of liver safety.

Paul H. Cottu

e14647

Preclinical studies evaluate pivotal TNFα nanomedicine clinical trial design.

Naris Nilubol

e14646

Preclinical testing of ultra-rapid FLASH total abdominal irradiation demonstrates survival benefit and decreased gastrointestinal toxicity compared to conventional external beam radiation.

Karen Levy

3092

Prognostic significance of amplifications of stemness genes in primary luminal breast cancer depending on the response to neoadjuvant chemotherapy.

Polina Kazantseva

e14655

Real-world application of next generation sequencing to guide therapeutic options in lymphoma.

Molly Tokaz

e14645

RERG involvement in the RAS pathway and ER-dependent transcription in breast cancer.

Pei-Chen Hsu

e14638

Role of ultrasound contrast agent in a tertiary cancer center: Experience in 75 patients with liver biopsy.

Amir Ata Rahnemai-Azar

e14671

SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors.

David S. Hong

TPS3160

Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC).

Valentino Cattori

3105

The chick embryo chorioallantoic membrane assay: In ovo model for personalized assessment and evaluation of the most effective therapeutic approach in cancer therapy.

Shiran Shapira

e14634

The Circulating Cell-free Genome Atlas (CCGA) Study: Size selection of cell-free DNA (cfDNA) fragments.

Darya Filippova

3103

The landscape of RET alterations from 56,970 adult patients with cancer: Clinical implications.

Alexander Andreev-Drakhlin

3106

Thyrointegrin αvβ3 nano targeted delivery of chemotherapy into solid tumors and its microenvironment.

Dhruba J. Bharali

e14661

TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA.

Tomoko Jogo

TPS3156

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial.

Jobst C. von Einem

e14648

Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.

Ranjit Bindra

e14664

Utilizing data from patient-derived xenograft mouse models of human tumors to inform clinical decision making in Molecular Tumor Boards (MTB) deliberations.

Jens Rueter

e14660